Corbus Pharmaceuticals Holdings, Inc. (CRBP) Director Buys $70,800.00 in Stock

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Director David P. Hochman acquired 10,000 shares of the stock in a transaction dated Friday, November 10th. The stock was acquired at an average cost of $7.08 per share, for a total transaction of $70,800.00. Following the purchase, the director now directly owns 459,500 shares in the company, valued at $3,253,260. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) traded up $0.20 during trading on Monday, hitting $7.25. 936,400 shares of the stock traded hands, compared to its average volume of 811,531. Corbus Pharmaceuticals Holdings, Inc. has a 1-year low of $5.30 and a 1-year high of $10.50.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. The business had revenue of $0.80 million for the quarter. Corbus Pharmaceuticals Holdings had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. research analysts predict that Corbus Pharmaceuticals Holdings, Inc. will post -0.63 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/11/13/corbus-pharmaceuticals-holdings-inc-crbp-director-buys-70800-00-in-stock.html.

Several brokerages have recently issued reports on CRBP. Noble Financial reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Corbus Pharmaceuticals Holdings in a research note on Friday, September 29th. Cantor Fitzgerald set a $24.00 price objective on shares of Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a research note on Monday, July 17th. ValuEngine cut shares of Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research note on Wednesday, September 13th. Finally, BidaskClub raised shares of Corbus Pharmaceuticals Holdings from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $20.75.

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in shares of Corbus Pharmaceuticals Holdings by 24.5% during the second quarter. Vanguard Group Inc. now owns 1,563,408 shares of the biopharmaceutical company’s stock worth $9,850,000 after purchasing an additional 307,979 shares during the period. State Street Corp boosted its holdings in shares of Corbus Pharmaceuticals Holdings by 2,998.2% during the second quarter. State Street Corp now owns 588,662 shares of the biopharmaceutical company’s stock worth $3,708,000 after purchasing an additional 569,662 shares during the period. Northern Trust Corp boosted its holdings in shares of Corbus Pharmaceuticals Holdings by 814.3% during the second quarter. Northern Trust Corp now owns 482,337 shares of the biopharmaceutical company’s stock worth $3,039,000 after purchasing an additional 429,584 shares during the period. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Corbus Pharmaceuticals Holdings by 4.3% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 444,504 shares of the biopharmaceutical company’s stock worth $3,178,000 after purchasing an additional 18,224 shares during the period. Finally, Artal Group S.A. acquired a new stake in shares of Corbus Pharmaceuticals Holdings during the second quarter worth approximately $1,575,000. Institutional investors and hedge funds own 29.20% of the company’s stock.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply